Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung
控制肺癌前病变进展为腺癌的机制
基本信息
- 批准号:9459856
- 负责人:
- 金额:$ 31.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:A549AblationAddressAdenocarcinomaBindingBinding ProteinsBiochemicalBypassCAV1 geneCancer EtiologyCancer PatientCell AgingCellsCessation of lifeCollectionDNA DamageDataDevelopmentDown-RegulationEpithelial CellsExperimental DesignsFRAP1 geneFutureGene ExpressionGenesGeneticGenetic ScreeningGrowthGuanine NucleotidesHistologicHomologous GeneHumanIn VitroInvestigationKRAS2 geneKnockout MiceLesionLibrariesLinkLungLung AdenocarcinomaLung NeoplasmsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMediatingMolecularMusMutationNon-Small-Cell Lung CarcinomaOncogenesOncogenicOxidative StressOxidesPathogenesisPathway interactionsPharmacologyPremalignantPublishingPurinesReactive Oxygen SpeciesScaffolding ProteinSignal TransductionSignaling MoleculeSirolimusSoft Agar AssayTestingTherapeuticTumor Suppressor ProteinsUnited StatesWomancancer cellcancer diagnosiscancer typecaveolin 1genetic approachin vivoinsightmenmigrationmouse modelnovelnovel therapeutic interventionoverexpressionoxidationpreclinical studyprematurepressurepreventprotein Kresponsesenescencesmall hairpin RNAsubcutaneoustumortumor xenografttumorigenic
项目摘要
Oncogenic K-Ras triggers cellular senescence by raising intracellular levels of reactive oxygen species. K-Ras-
expressing cells need to bypass the oncogene-induced senescence (OIS) barrier to progress to higher grades
of malignancy. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and
adenocarcinoma is the most common type of NSCLC. K-Ras mutations represent the most common molecular
change in lung adenocarcinomas. Progression from pre-malignant lesions to malignant adenocarcinomas is a
hallmark of NSCLC pathogenesis. Our proposed investigations will directly address Provocative
Question #1 by identifying and functionally characterizing novel molecular mechanisms that control the
transition from premalignant lung lesions to adenocarcinomas and whose inhibition has the potential to prevent
NSCLC development.
Central hypothesis: we advance the novel paradigm that caveolin-1 controls the fate of lung epithelial
cells in response to oncogenic Ras. We propose that oncogenic K-Ras induces senescence in premalignant
lung lesions through a caveolin-1-mediated pro-oxidative signaling and that downregulation of caveolin-1
expression is necessary to bypass OIS and drive the progression to malignant adenocarcinomas.
This hypothesis will be tested by pursuing three specific aims:
Aim 1: Determine how caveolin-1 promotes oncogenic K-Ras-induced cellular senescence. Hypothesis:
inhibition of MTH1 function by caveolin-1 is promoted by oncogenic K-Ras via mTOR activation, which leads to
enhanced purine oxidation, sustained DNA damage response (DDR) and cellular senescence in lung epithelial
cells.
Aim 2: Identify how oncogenic K-Ras-expressing cells bypass OIS. Hypothesis: a selective pressure exists
in oncogenic K-Ras-expressing cells that downregulates caveolin-1 gene expression to elude OIS.
Aim 3: Determine if a lack of caveolin-1 promotes the progression to adenocarcinomas in mouse
models of oncogene-induced lung cancer. Hypothesis: Caveolin-1-mediated OIS is a tumor suppressor
mechanism: the genetic ablation of caveolin-1 inhibits the formation of premalignant and senescent-positive
lung lesions in favor of malignant and senescent-negative adenocarcinomas.
These investigations propose the novel concept that targeting K-Ras-dependent signaling that bypasses OIS
through downregulaton of caveolin-1 expression, which will be identified in this proposal, is an alternative and
better therapeutic option then targeting K-Ras itself: it will allow the selective inhibition of pro-tumorigenic K-
Ras signaling while rescuing pro-senescent K-Ras pathways. This new information has the potential to directly
impact the development of novel therapeutic interventions to prevent the progression to lung
adenocarcinomas.
致癌性K-Ras通过提高细胞内活性氧水平触发细胞衰老。克-拉斯-
表达癌基因的细胞需要绕过癌基因诱导的衰老(OIS)屏障才能进展到更高的级别
恶性肿瘤非小细胞肺癌(NSCLC)是最常见的肺癌形式,
腺癌是最常见的NSCLC类型。K-Ras突变代表了最常见的
肺腺癌的变化。从癌前病变进展为恶性腺癌是一个重要的因素。
NSCLC发病机制的标志。我们提议的调查将直接针对挑衅性
问题#1通过识别和功能性表征新的分子机制,控制
从癌前肺病变向腺癌的转变,并且其抑制有可能预防
非小细胞肺癌发展。
中心假设:我们提出了新的范式,即小窝蛋白-1控制肺上皮细胞的命运,
细胞对致癌Ras的反应。我们认为致癌K-Ras诱导癌前病变细胞衰老,
通过小窝蛋白-1介导的促氧化信号传导和小窝蛋白-1的下调导致肺损伤
表达是绕过OIS并驱动向恶性腺癌进展所必需的。
将通过追求三个具体目标来检验这一假设:
目的1:确定小窝蛋白-1如何促进致癌K-Ras诱导的细胞衰老。假设:
致癌K-Ras通过mTOR激活促进小窝蛋白-1对MTH 1功能的抑制,这导致
肺上皮细胞嘌呤氧化增强、持续DNA损伤反应(DDR)和细胞衰老
细胞
目的2:确定致癌K-Ras表达细胞如何绕过OIS。假设:存在选择性压力
在表达致癌K-Ras的细胞中,下调小窝蛋白-1基因表达以逃避OIS。
目的3:确定缺乏小窝蛋白-1是否促进小鼠腺癌的进展
癌基因诱导的肺癌模型。假设:小窝蛋白-1介导的OIS是肿瘤抑制因子
机制:基因切除小窝蛋白-1抑制癌前病变和衰老阳性细胞的形成。
肺部病变有利于恶性和衰老阴性腺癌。
这些研究提出了靶向绕过OIS的K-Ras依赖性信号传导的新概念
通过下调小窝蛋白-1的表达,这将在本建议中确定,是一种替代方法,
更好的治疗选择,然后靶向K-Ras本身:它将允许选择性抑制促肿瘤发生的K-
Ras信号转导,同时拯救促衰老K-Ras通路。这些新信息有可能直接
影响新型治疗干预措施的开发,以防止进展到肺
腺癌
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FERRUCCIO GALBIATI其他文献
FERRUCCIO GALBIATI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FERRUCCIO GALBIATI', 18)}}的其他基金
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung
控制肺癌前病变进展为腺癌的机制
- 批准号:
9305499 - 财政年份:2017
- 资助金额:
$ 31.25万 - 项目类别:
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung
控制肺癌前病变进展为腺癌的机制
- 批准号:
9899946 - 财政年份:2017
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease
Caveolin-1介导的衰老、慢性炎症和年龄相关性肺部疾病
- 批准号:
9279206 - 财政年份:2015
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease
Caveolin-1介导的衰老、慢性炎症和年龄相关性肺部疾病
- 批准号:
9059176 - 财政年份:2015
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease
Caveolin-1介导的衰老、慢性炎症和年龄相关性肺部疾病
- 批准号:
8903586 - 财政年份:2014
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
Caveolin 1:PP2A/ATM/p53 通路的新型调节剂
- 批准号:
8507585 - 财政年份:2009
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
Caveolin 1:PP2A/ATM/p53 通路的新型调节剂
- 批准号:
8114097 - 财政年份:2009
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
Caveolin 1:PP2A/ATM/p53 通路的新型调节剂
- 批准号:
8301580 - 财政年份:2009
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
Caveolin 1:PP2A/ATM/p53 通路的新型调节剂
- 批准号:
7903303 - 财政年份:2009
- 资助金额:
$ 31.25万 - 项目类别:
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway
Caveolin 1:PP2A/ATM/p53 通路的新型调节剂
- 批准号:
7574065 - 财政年份:2009
- 资助金额:
$ 31.25万 - 项目类别:
相似海外基金
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Standard Grant
Collaborative Research: CDS&E: An experimentally validated, interactive, data-enabled scientific computing platform for cardiac tissue ablation characterization and monitoring
合作研究:CDS
- 批准号:
2245152 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Standard Grant














{{item.name}}会员




